None
Quote | Autolus Therapeutics plc (NASDAQ:AUTL)
Last: | $3.45 |
---|---|
Change Percent: | -0.29% |
Open: | $3.5 |
Close: | $3.45 |
High: | $3.52 |
Low: | $3.29 |
Volume: | 1,575,755 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Autolus Therapeutics plc (NASDAQ:AUTL)
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...
2024-05-17 13:52:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Autolus Therapeutics (NASDAQ: AUTL ) just reported results for the first quarter of 2024. Autolus Therapeutics reported earnings per share of -24 cents. This was below the...
Message Board Posts | Autolus Therapeutics plc (NASDAQ:AUTL)
Subject | By | Source | When |
---|---|---|---|
Found an interesting article | jondoeuk | investorshub | 05/11/2023 6:32:42 PM |
$AUTL good read | jondoeuk | investorshub | 05/11/2023 10:18:44 AM |
great article | jondoeuk | investorshub | 05/11/2023 6:41:46 AM |
The now last up | jondoeuk | investorshub | 05/11/2023 4:44:23 AM |
MomentumIts now last up | jondoeuk | investorshub | 05/09/2023 11:12:12 AM |
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (M...